Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Ovarian cancer treatment has been revolutionized by poly(ADP-ribose) polymerase (PARP) inhibitors.
• Niraparib is a potent PARP inhibitor demonstrating significant efficacy in various ovarian cancer settings.
• PARP inhibitors exploit synthetic lethality by targeting DNA repair pathways often deficient in ovarian cancers, especially those with BRCA mutations.

Purpose of the Study:

• To review the efficacy and safety of niraparib in ovarian cancer treatment.
• To discuss the mechanism of action and clinical trial data supporting niraparib's use.
• To highlight niraparib's distinct toxicity profile compared to other PARP inhibitors.

Main Methods:

• Review of pivotal clinical trials (PRIMA, ENGOT-OV16/NOVA, QUADRA) evaluating niraparib.
• Analysis of niraparib's mechanism of action in targeting homologous recombination DNA repair.
• Examination of niraparib's safety and tolerability data, focusing on adverse events.

Main Results:

• Niraparib demonstrated substantial efficacy in both first-line and recurrent ovarian cancer.
• Clinical trials have established niraparib as a key therapeutic option.
• Niraparib is associated with a distinct toxicity profile, including notable Grade 3-4 hematologic toxicities (thrombocytopenia) and hypertension.

Conclusions:

• Niraparib is an effective PARP inhibitor for ovarian cancer, offering significant clinical benefits.
• Understanding niraparib's specific efficacy and safety profile is crucial for clinical application.
• Optimal patient selection and management are essential for maximizing therapeutic outcomes while mitigating risks.